Active

Atchoo! Can understanding allergic reactions lead to new cancer treatments?

Cancer types:

Melanoma

Project period:

Research institute:

King's College London

Award amount:

£274,912

Location:

United Kingdom

Professor Sophia Karagiannis
Researcher Professor Sophia Karagiannis

Professor Sophia Karagiannis and her team are investigating if IgE, a type of antibody that has not been used in cancer therapy yet could improve the effectiveness of immunotherapy.

Hope for the future

In 2022, there were just over 330,000 cases of the skin cancer melanoma globally. In recent years, immunotherapy using our body’s own defense system of antibodies has provided a new treatment option for people with melanoma. However, half of patients with melanoma currently do not respond to this therapy and we don’t understand why. Professor Karagiannis’ project hopes to find new solutions to treatment resistance and boost immunotherapy, helping more melanoma patients.

Professor Sophia Karagiannis Team
Meet the scientist

As well as her career as a cancer immunologist, Professor Karagiannis is married and a mum of two sons, a strong supporter of women and girls in science and medicine, and a firm believer in the power of friendship, mentorship and collaboration in all aspects of personal, family and working life. She believes that by working together across sectors and disciplines there is nothing we could not accomplish and no obstacle that we cannot overcome.

The science

Antibodies are protective proteins present throughout your body that your immune system produces. They each have a very specific shape that can bind to a specific threat, like a key that fits perfectly into a lock.

In recent years cancer drugs made with antibodies have revolutionized cancer treatment but they only work a limited number of patients and we still don’t understand why. These drugs are based on one type of antibody, called IgG. Humans, however, have 9 different types of antibodies in total, and Professor Karagiannis wants to find out if another type of antibody, IgE, could also be adapted for cancer treatment. IgE antibodies are involved in allergic reactions, so you can thank them for a runny nose and itchy eyes if you have hay fever. In this project, they want to study the structure of IgE, to research the most effective way of making IgE useful in cancer therapeutics.
 

This project is truly collaborative, connecting researchers across the country. Professor Karagiannis at King's College London is working together with Professor Ungar at the University of York, Dr Wagner at Queen’s University Belfast and the biopharmaceutical company Ludger Ltd, to bring together the expertise needed to tackle this. The only way we can unlock new cancer cures is by working together.

Together, we are looking at how this knowledge can help us to design better therapies and preventive approaches. These efforts could only be undertaken, and outcomes could only be accomplished, if we work together through international links.

Professor Sophia Karagiannis
Professor Sophia Karagiannis

Related projects

Adam Hurlstone Team

Active United Kingdom

Melanoma

Why do some melanoma patients stop responding to therapy?

Researchers hope to find new drug targets that could make immunotherapies more effective, making them a better option for more people with advanced melanoma.

Researcher: Dr Adam Hurlstone

Reversing resistance to immune checkpoint inhibitors
Victoria Sanz Moreno in the Lab

Active United Kingdom

Melanoma

How does melanoma adapt to spread and seed new tumours?

Cancers is easier to treat when caught early so this project hopes to reveal new treatments that could stop melanoma spreading, helping survival rates.

Researcher: Professor Victoria Sanz-Moreno

Understanding how melanoma adapts to spread and seed new tumours
Ruth Ganss Teamshot

Active Australia

Melanoma

Can our blood vessels help immunotherapy work better for melanoma?

Immunotherapy has helped improve melanoma survival rates but it doesn’t work for everyone so this project hopes to find ways for more patients to benefit.

Researcher: Professor Ruth Ganss

Improving the effect of immunotherapies for melanoma skin cancer
Share this page